Lupin Limited has announced a revised timeline for the transfer of its API R&D division and Over-the-Counter (OTC) Consumer Healthcare business. In a regulatory filing on April 30, 2025, the company stated that the Business Transfer Agreements (BTAs) for both units are now expected to be executed by June 30, 2025, instead of the previously communicated date of April 30, 2025.
As per the update, the API R&D division will be transferred to Lupin Manufacturing Solutions Limited (LMSL), and the OTC Consumer Healthcare business will be transferred to Lupinlife Consumer Healthcare Limited (LCHL). Both are wholly owned subsidiaries of Lupin.
The transactions are being executed on a slump sale basis, and the company emphasized that the revised date may still be subject to mutual agreement between the parties involved.
This modification comes after previous disclosures dated February 11 and March 31, 2025, where Lupin had outlined the strategic restructuring of its business segments in line with regulatory obligations under SEBI Listing Regulations.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
